Zylox-Tonbridge Medical Technology Co., Ltd. Class H
2.28
EUR
-0.12
(-5.00%)
ISIN
CNE100004JD2
Return %
Stock
S&P 500
1Y
-13.64
14.20
3Y
93.22
81.12
5Y
-42.71
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhong Zhao
- Full Time Employees
- 925
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Zylox-Tonbridge Industrial Park Hangzhou ZH China 311121
- IPO Date
- Jul 5, 2021
- Website
- zyloxtb.com
- Similar Companies
- Business
- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) is a leading China-based medical device company specializing in the research, development, manufacturing, and commercialization of neurovascular and peripheral vascular interventional devices for physicians and patients. Founded in 2012 and headquartered in Hangzhou, China, the company offers a comprehensive portfolio exceeding 60 products, including neurovascular devices such as the Phoenix Neurovascular Embolization Coil, Thrombite Clot Retriever Device, White Horse Intracranial Balloon Catheter, clot retriever stents, aspiration catheters, and intracranial access systems for ischemic stroke, hemorrhagic stroke, intracranial stenosis, and carotid artery treatments; peripheral vascular products encompassing stents like Zenflex Peripheral Stent System and Zenflex Pro Peripheral Drug-eluting Stent System, drug-coated balloons such as UltraFree Drug-coated PTA Balloon Catheter and Zenfluxion Drug-Coated PTA Balloon Catheter, PTA balloon catheters including ZenFlow PTA Balloon Catheter and ZenFlow II PTA Balloon Catheter, venous stents like Zynlastic Peripheral Venous Stent System, vena cava filters such as Zylox Octoplus Vena Cava Filter, thrombus aspiration systems including ZYLOX Eagle Peripheral Thrombus Aspiration System, peripheral embolization coils like Zylox Phoenix Peripheral Fibered Detachable Coil Occlusion System, vascular closure devices such as ZYLOX Unicorn Vascular Closure Device, snare kits, and hemodialysis access solutions like Zenflow Pufferfish Scoring Balloon Catheter; as well as technical consultation services and material imports. The company operates primarily in the People's Republic of China with international reach and maintains manufacturing facilities in Hangzhou and Zhuhai. Recent developments include its listing on the Main Board of the Hong Kong Stock Exchange in July 2022 under stock code 2190, National Medical Products Administration approvals in 2023 for four key products comprising clot retriever stent, aspiration catheter, PTA drug-coated balloon catheter, and snare retrieval kit for IVC filter, a strategic partnership and up to $15 million equity funding agreement with Avinger Inc. announced in March 2024 to access the Greater China market and distribute peripheral vascular products in the U.S. and Germany, strong financial performance with full-year profit in 2024 and over 76% year-over-year net profit surge in interim 2025 results, and regulatory approval for the ZYLOX Unicorn Vascular Closure Device along with product demonstrations at events like the 2025 Boao forum.
Company News
Zylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy